Cargando…

A novel EGFR-TKI inhibitor (cAMP-H(3)BO(3)complex) combined with thermal therapy is a promising strategy to improve lung cancer treatment outcomes

PURPOSE: Although EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) induce favorable responses as first-line non-small cell lung cancer treatments, drug resistance remains a serious problem. Meanwhile, thermal therapy also shows promise as a cancer therapy strategy. Here we com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Yongpeng, Huang, Chunliu, Zhang, Junfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593564/ https://www.ncbi.nlm.nih.gov/pubmed/28915593 http://dx.doi.org/10.18632/oncotarget.17628

Ejemplares similares

EGFR induces DNA decomposition via phosphodiester bond cleavage
por: Tong, Yongpeng, et al.
Publicado: (2017)

Cyclic 3', 5'-AMP relay in dictyostelium discoideum. IV. Recovery of the cAMP signaling response after adaptation to cAMP
por: Dinauer, M, et al.
Publicado: (1980)

Cyclic 3', 5'-AMP relay dictyostelium discoideum. V. Adaptation of the cAMP signaling response during cAMP stimulation
por: Dinauer, M, et al.
Publicado: (1980)

Cyclic 3',5'-AMP relay in Dictyostelium discoideum III. The relationship of cAMP synthesis and secretion during the cAMP signaling response
Publicado: (1980)

cAMP Is a Promising Regulatory Molecule for Plant Adaptation to Heat Stress
por: Liang, Shuang, et al.
Publicado: (2022)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Multiple Facets of cAMP Signalling and Physiological Impact: cAMP Compartmentalization in the Lung
por: Oldenburger, Anouk, et al.
Publicado: (2012)

MEK Inhibitors Reverse cAMP-Mediated Anxiety in Zebrafish
por: Lundegaard, Pia R., et al.
Publicado: (2015)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

Oscillatory cAMP signaling rapidly alters H3K4 methylation
por: Huff, Tyler C, et al.
Publicado: (2019)

cAMP crosses junctions
por: Bashyam, Hema
Publicado: (2007)

Mitochondrial cAMP signaling
por: Zhang, Fan, et al.
Publicado: (2016)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
por: Arasada, Rajeswara Rao, et al.
Publicado: (2018)

A novel RRGW derived peptide is a promising inhibitor of BoNT/A
por: Ma, Wantong, et al.
Publicado: (2023)

Synthesis, Thermal Analysis, Spectroscopic Properties, and Degradation Process of Tutton Salts Doped with AgNO(3) or H(3)BO(3)
por: Pacheco, Tiago S., et al.
Publicado: (2023)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors
por: Beaulieu, Jean-Martin, et al.
Publicado: (2011)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
por: Lee, Sanghun, et al.
Publicado: (2018)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
por: Fang, Wenfeng, et al.
Publicado: (2020)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

EHMTI-0033. The phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cAMP increase
por: Song, G, et al.
Publicado: (2014)

Suppression of Virulence of Toxigenic Vibrio cholerae by Anethole through the Cyclic AMP (cAMP)-cAMP Receptor Protein Signaling System
por: Zahid, M. Shamim Hasan, et al.
Publicado: (2015)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Imaging cAMP nanodomains in the heart
por: Chao, Ying-Chi, et al.
Publicado: (2019)

EGFR-TKI不良反应管理专家共识
Publicado: (2019)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019)

“cAMP Sponge”: A Buffer for Cyclic Adenosine 3′, 5′-Monophosphate
por: Lefkimmiatis, Konstantinos, et al.
Publicado: (2009)

Phosphodiesterase 4 inhibitors and db-cAMP inhibit TNF-α release from human mononuclear cells. Effects of cAMP and cGMP-dependent protein kinase inhibitors
por: Hichami, A., et al.
Publicado: (1996)

cAMP is an allosteric modulator of DNA-binding specificity in the cAMP receptor protein from Mycobacterium tuberculosis
por: Gárate, Fernanda, et al.
Publicado: (2021)

An Improved Genetically Encoded Fluorescent cAMP Indicator for Sensitive cAMP Imaging and Fast Drug Screening
por: Liu, Wenfeng, et al.
Publicado: (2022)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
por: Seki, Nobuhiko, et al.
Publicado: (2019)

High quantum efficiency and excellent color purity of red-emitting Eu(3+)-heavily doped Gd(BO(2))(3)-Y(3)BO(6)-GdBO(3) phosphors for NUV-pumped WLED applications
por: Tran, Manh Trung, et al.
Publicado: (2023)

Direct regulation of the natural competence regulator gene tfoX by cyclic AMP (cAMP) and cAMP receptor protein (CRP) in Vibrios
por: Wu, Rui, et al.
Publicado: (2015)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gio27p93rsi9d24999lmc5tbh7